TrialJournal of the European Academy of Dermatology and Venereology : JEADV2022

Characterizing the relationships between patient-reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib.

R Winnette et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.